New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Bristol Myers Squibb Company

BMY

Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.

Revenue
+6.93%
EPS
−2.78%
Free cash flow
−36.0%
Total debt
−12.5%

Quarter to September 2026, against a year earlier

59.45 1.11 +1.90%
Market cap
$119.3B
P/E
12.9×
Fwd P/E FY26e
12.0×
Dividend yield
4.32%
F-score
8/9
ROIC
13.2%
Net debt / EBITDA
2.6×
Payout ratio
0.6×

Bristol Myers Squibb Company (BMY) SEC filings, changes and red flags

Red flags

No red flags have been raised by Bristol Myers Squibb Company’s filings on file.

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 11 added · 7 removed · 38 modified
P2I1A: no material changes, the filing says
8-K Oct 29, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 11 added · 9 removed · 42 modified
P2I1A: no material changes, the filing says
8-K Jul 30, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K May 5, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026 P1I2: 33 added · 86 removed · 30 modified
P2I1A: no material changes, the filing says
8-K Apr 30, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 10 added · 8 removed · 52 modified
1A: 4 added · 1 removed · 51 modified
7: 55 added · 50 removed · 74 modified
8-K Feb 5, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Nov 17, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Oct 31, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 3, 2025 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025 P1I2: 14 added · 17 removed · 53 modified
P2I1A: no material changes, the filing says
8-K Oct 30, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025 P1I2: 28 added · 11 removed · 56 modified
P2I1A: no material changes, the filing says
8-K Jul 31, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K Apr 24, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-K Dec 31, 2024 1: no comparison — no earlier filing on file
1A: no comparison — no earlier filing on file
7: no comparison — no earlier filing on file
8-K Feb 6, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 31, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Jul 26, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Apr 25, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Feb 2, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.